UroGen Pharma (URGN) Share-based Compensation (2017 - 2026)

UroGen Pharma (URGN) has reported Share-based Compensation for 10 consecutive years, with $39.1 million the latest figure, recorded in Q1 2026.

• Quarterly Share-based Compensation rose 1174.03% year-over-year to $39.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.1 million (up 191.33% YoY) and the FY2025 annual result came in at $12.0 million, down 8.77% from the prior year.
• Share-based Compensation rose to $39.1 million in Q1 2026 per URGN's latest filing, from $3.1 million in the prior quarter.
• Over the last five years, Share-based Compensation for URGN reached as high as $39.1 million in Q1 2026 and fell as low as $2.2 million in Q2 2023.
• A 5-year average of $5.9 million and a median of $2.9 million in 2022 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2022 — Share-based Compensation slumped 55.8% — and 2026, when it surged 1174.03%.
• Year by year, Share-based Compensation stood at $2.4 million in 2022, then advanced by 10.3% to $2.6 million in 2023, then climbed by 26.45% to $3.3 million in 2024, then fell by 5.24% to $3.1 million in 2025, then jumped by 1149.2% to $39.1 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $39.1 million, $3.1 million, and $3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.